Race Oncology Ltd. (AU:RAC)
ASX:RAC
Want to see AU:RAC full AI Analyst Report?
RAC Stock Chart & Stats
AU$2.70
-AU$0.03(-2.27%)
At close: 4:00 PM EST
AU$2.70
-AU$0.03(-2.27%)
Day’s Range― - ―
52-Week RangeAU$0.97 - AU$4.90
Previous CloseN/A
Volume68.10K
Average Volume (3M)373.28K
Market Cap
AU$520.10M
Enterprise ValueAU$499.16M
Total Cash (Recent Filing)AU$20.94M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding183,780,080
10 Day Avg. Volume310,625
30 Day Avg. Volume373,283
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)12.69
Price to Sales (P/S)33.63
P/FCF Ratio-44.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially reduces refinancing and interest-rate risk, giving management flexibility to fund clinical programs via equity or partnerships rather than servicing debt. This durability supports R&D timelines and strategic optionality over the next 2–6 months.
Strong FY2025 Gross MarginA materially stronger gross margin in FY2025 implies improved revenue quality or lower direct costs, which is durable if maintained. Higher gross margins create operating leverage potential as revenues recover, improving the probability of sustainable profitability as scale or partnerships expand.
Improving Cash Burn And Narrower LossesA reduced cash burn and narrower FY2025 losses show management progress on cost control and operational efficiency. If sustained, this trend lengthens runway, reduces near-term financing needs and increases the chance clinical progress can be funded or partnered without immediate large equity raises.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative OCF and FCF indicate the business is not self-funding and remains reliant on external financing. Over months this creates dilution or partnership pressure, constrains investment choices, and heightens execution risk if capital markets or partner terms tighten.
Revenue Volatility And FY2025 DeclineSharp revenue swings and a marked FY2025 decline point to an uneven commercialization trajectory and uncertain market adoption. Such structural volatility complicates forecasting, weakens operating leverage and could delay breakeven or scale-up plans absent clearer, repeatable revenue drivers.
Equity Erosion & Negative Returns On EquityDeclining equity and materially negative ROE reflect ongoing losses that erode shareholder capital. Over time this limits internal funding capacity, raises governance and investor-return concerns, and increases dependence on external capital which may be dilutive or costly.
Race Oncology Ltd. News
RAC FAQ
What was Race Oncology Ltd.’s price range in the past 12 months?
Race Oncology Ltd. lowest share price was AU$0.97 and its highest was AU$4.90 in the past 12 months.
What is Race Oncology Ltd.’s market cap?
Race Oncology Ltd.’s market cap is AU$520.10M.
When is Race Oncology Ltd.’s upcoming earnings report date?
Race Oncology Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 116 days.
How were Race Oncology Ltd.’s earnings last quarter?
Race Oncology Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.
Is Race Oncology Ltd. overvalued?
According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued.
Does Race Oncology Ltd. pay dividends?
Race Oncology Ltd. does not currently pay dividends.
What is Race Oncology Ltd.’s EPS estimate?
Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Race Oncology Ltd. have?
Race Oncology Ltd. has 183,780,080 shares outstanding.
What happened to Race Oncology Ltd.’s price movement after its last earnings report?
Race Oncology Ltd. reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.646%.
Which hedge fund is a major shareholder of Race Oncology Ltd.?
Currently, no hedge funds are holding shares in AU:RAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Race Oncology Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RAC Sentiment 99%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$110.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.34%
12-Months-Change
Fundamentals
Return on Equity
-47.44%
Trailing 12-Months
Asset Growth
14.28%
Trailing 12-Months
Company Description
Race Oncology Ltd.
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
Technical Analysis
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---